Day One Biopharmaceuticals, LLC
https://dayonebio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Day One Biopharmaceuticals, LLC
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Project Optimus For Kids: US FDA Aims To Improve Dosage Optimization For Pediatric Cancer Drugs
Pediatric studies of promising cancer drugs can begin before the ideal dose is identified for adults, although some dose optimization work in children may be better left to the postmarket setting, advisory committee members said.
Finance Watch: No Big Post-ASCO Follow-On Frenzy, But Biotech Had A Good Week
Public Company Edition: Follow-on offerings did not surge after ASCO, but Day One and Cogent raised $150m-plus. Also, IQVIA and Ionis sold $1.25bn and $500m in notes, while Krystal and Lexicon grossed $160m and $125m from post-approval offerings.
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- DOT Therapeutics-1, Inc.
- DOT-1
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice